Open AccessRacial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare
Author(s) -
Jifang Zhou,
Karen Sweiss,
Edith A. Nutescu,
Jin Han,
Pritesh Patel,
Naomi Ko,
Todd A. Lee,
Brian C.H. Chiu,
Gregory S. Calip
Publication year - 2021
Publication title -
jco oncology practice
Language(s) - English
Resource type - Journals
eISSN - 2688-1535
pISSN - 2688-1527
DOI - 10.1200/op.20.00479
Subject(s) - medicine , discontinuation , bisphosphonate , retrospective cohort study , pacific islanders , multiple myeloma , population , hazard ratio , cohort , surgery , osteoporosis , confidence interval , environmental health
Intravenous (IV) bisphosphonates reduce the risk of skeletal-related events in patients with multiple myeloma (MM). However, data describing racial differences in IV bisphosphonate utilization outside of clinical trial settings are limited. We evaluated population-level IV bisphosphonate initiation and discontinuation among patients of age ≥ 65 years with MM.